



Moderna to Highlight its mRNA Development Candidate Pipeline at 2017 J.P. Morgan Healthcare Conference

January 3, 2017

CAMBRIDGE, Mass., January 3, 2017 — Moderna Therapeutics, a clinical stage biotechnology company pioneering messenger RNA (mRNA) Therapeutics™ to create a new generation of transformative medicines for patients, announced today that Stéphane Bancel, Chief Executive Officer, will present the company's advancing pipeline, which currently includes 12 mRNA development candidates, at the 35th Annual J.P. Morgan Healthcare Conference.

Mr. Bancel's presentation will take place on Monday, January 9, 2017 at 2:30 p.m. PT in Elizabethan Room C/D at The Westin St. Francis Hotel in San Francisco.

About Moderna Therapeutics

Moderna Therapeutics is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA medicines through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures include Valera (infectious diseases), Onkaido (immuno-oncology), Caperna (personalized cancer vaccines) and Elpidera (rare diseases). Founded by Flagship VentureLabs®, Cambridge-based Moderna is privately held and currently has strategic agreements with [AstraZeneca](#), [Alexion Pharmaceuticals](#), [Merck](#) and [Vertex Pharmaceuticals](#). To learn more, visit www.modernatx.com.

Moderna Contacts:

Investors:

Maren Winnick
617-674-5297

maren.winnick@modernatx.com

Media:

Liz Melone

617-256-6622 liz.melone@modernatx.com